American Society for Clinical Oncology, June 3-7 – Consumer Health News

The annual meeting of the American Society of Clinical Oncology was held June 3-7 in Chicago and attracted more than 40,000 attendees from around the world, including clinicians, academics, allied health professionals and other interested individuals by oncology. The conference featured the latest advances in clinical cancer research, including oral abstract presentations and poster presentations in disease and specialty areas. Presentations focused on new targeted therapies as well as improvements in chemotherapy and radiotherapy approaches.

In the TROPiCS-02 Phase 3 clinical trial, Hope S. Rugo, MD, of the University of California, San Francisco Comprehensive Cancer Center, and colleagues found that the use of sacituzumab govitecan improves median disease-free survival. progression (PFS) compared to standard chemotherapy in patients with hormone-resistant hormone receptor positive and human epidermal growth factor receptor 2 (HR+/HER2−) negative heavily pretreated metastatic breast cancer.

The authors assessed the efficacy of sacituzumab govitecan versus physician’s choice chemotherapy for HR+/HER2− advanced breast cancer. Across 113 international sites, 543 patients with HR+/HER2− metastatic breast cancer who had been treated with hormone therapy, CDK4/6 inhibitors and two to four chemotherapy regimens were recruited. Researchers found that sacituzumab govitecan improved median PFS by 34% compared to standard chemotherapy; there was also a non-significant trend observed in overall survival. The overall response rate was 21% for those who received sacituzumab govitecan, compared with 14% for those who received standard chemotherapy. Additionally, the researchers found that the rate of clinical benefit and the median duration of response were both favorable to sacituzumab govitecan.

“In TROPiCS-02, sacituzumab was studied in very heavily pretreated hormone receptor positive advanced breast cancer patients with very limited options, and offers potential for an effective alternative therapy for these patients,” Rugo said. “Overall, it is important to have new treatment options, extend quality of life, and provide disease control for patients with advanced, highly pretreated hormone receptor cancer.”

The study was funded by Gilead Sciences, the maker of sacituzumab govitecan.

Press release

In the prospective single-arm Phase 3 LUMINA trial, Timothy Joseph Whelan, MD, of McMaster University and Juravinski Cancer Center in Hamilton, Ontario, Canada, and colleagues found that the recurrence rate is very low in women 55 years of age or older with luminal breast cancer not treated with radiation therapy.

The authors recruited 500 patients from 26 centers in Canada who had Grade 1 or 2 nodeless tumors less than 2 cm in size that had been removed by breast-conserving surgery and were luminal A tumors with a Ki67 tumor cell count of 13.25% or less. . The patients underwent breast-conserving surgery, followed by hormone therapy, but did not receive radiation therapy. At five years, the researchers found a 2.3% chance of local recurrence and a 1.9% chance of a new breast cancer developing in the breast not originally affected by the cancer. The disease-free survival rate was 97.3% and the disease-free survival rate was 89.9%. The overall survival rate was 97.2%.

“We tested a biomarker, which allows women aged 55 and over with low-grade type A luminal breast cancer to avoid radiation therapy, which can be expensive, time-consuming and associated with significant side effects” , Whelan said. “We found that in women 55 years or older with luminal A breast cancer treated without radiation therapy, the recurrence rate remains very low. As such, practicing clinicians may want to omit radiation therapy for this type of patient.”

Several authors disclosed financial ties to the pharmaceutical industry.

Press release

Eric Bouffet, MD, of the Hospital for Sick Children in Toronto, and colleagues found that the combination of dabrafenib and trametinib significantly increased the overall response rate in pediatric patients with BRAF Low-grade gliomas carrying the V600 mutation compared with the standard chemotherapy combination of carboplatin plus vincristine.

In a double-blind clinical trial, the authors randomly assigned 110 patients (ages 1 to 17) who had BRAF low-grade gliomas carrying the V600 mutation either on dabrafenib twice daily plus trametinib once daily or on standard doses of carboplatin plus vincristine. The researchers found that the combination of dabrafenib and trametinib resulted in an overall response rate of 47%, compared to 11% for the standard chemotherapy combination of carboplatin and vincristine. The researchers also observed significant improvements in clinical benefit rate, duration of response, time to response, PFS and overall survival in those who received dabrafenib and trametinib.

“For pediatric patients with BRAF V600-mutant low-grade glioma, dabrafenib plus trametinib may provide a better level of care,” Bouffet said in a statement. “This represents an important breakthrough for younger brain cancer patients because it is the first combination of targeted therapies developed for patients as young as [age 1 year].”

The study was funded by Novartis, the maker of dabrafenib and trametinib.

Press release

ASCO: Ramucirumab Plus Pembrolizumab promising in NSCLC

THURSDAY, June 9, 2022 (HealthDay News) — According to research presented at the annual meeting of the American Society of Clinical Oncology, held June 3-7 in Chicago.

Read the full text

ASCO: High risk of suicide among cancer patients in the United States

WEDNESDAY, June 8, 2022 (HealthDay News) — Patients diagnosed with cancer are at high risk of suicide, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held June 3-7. in Chicago.

Read the full text

ASCO: Ancestry-specific genetic risk examined for TNBC

WEDNESDAY, June 8, 2022 (HealthDay News) — Women of African descent more often have a personal history of triple-negative breast cancer, but the magnitude of gene-specific risks for triple-negative breast cancer is similar across different races/ethnicities groups, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held June 3-7 in Chicago.

Read the full text

ASCO: Black patients with metastatic breast cancer ready to consider clinical trials

TUESDAY, June 7, 2022 (HealthDay News) — Black patients with metastatic breast cancer are ready to consider entering clinical trials, according to a study presented at the annual meeting of the American Society of Clinical Oncology, which was held from June 3 to 7 in Chicago.

Read the full text

ASCO: Disparities observed in the use of telehealth for cancer care during the pandemic

TUESDAY, June 7, 2022 (HealthDay News) — Racial, geographic and socioeconomic disparities have been observed in the use of telehealth among patients starting cancer treatment during the COVID-19 pandemic, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held June 3-7 in Chicago.

Read the full text

ASCO: desmoplastic melanoma responds to neoadjuvant pembrolizumab

TUESDAY, June 7, 2022 (HealthDay News) — For patients with resectable desmoplastic melanoma, treatment with pembrolizumab before resection results in a high pathological complete response rate, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held June 3-7 in Chicago.

Read the full text

ASCO: ACA Medicaid expansion has improved access to cancer trials

TUESDAY, June 7, 2022 (HealthDay News) — Implementation of the Medicaid Expansion Affordable Care Act was associated with an increase in the proportion of patients using Medicaid in cancer clinical trials, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held June 3-7 in Chicago.

Read the full text

ASCO: Parental cancer linked to risk of unmet social needs in children

TUESDAY, June 7, 2022 (HealthDay News) — Parental cancer is associated with a greater likelihood of food insecurity at the family level, financial worries about housing costs and other monthly bills, and barriers to transportation to medical care for American children, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held June 3-7 in Chicago.

Read the full text

ASCO: cDNA analysis guides treatment for stage II colon cancer

MONDAY, June 6, 2022 (HealthDay News) — According to a study published online June 4 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held June 3-7 in Chicago.

Read the full text

ASCO: Increase in cancer-related deaths observed during the pandemic

MONDAY, June 6, 2022 (HealthDay News) — From 2019 to 2020, there was a 3.2% increase in cancer-related deaths, which was more than the expected number of deaths, according to a study presented at the meeting. annual meeting of the American Society of Clinical Oncology, held June 3-7 in Chicago.

Read the full text

ASCO: Supplemental ibrutinib slows mantle cell lymphoma in older adults

FRIDAY, June 3, 2022 (HealthDay News) — For elderly patients with untreated mantle cell lymphoma, adding ibrutinib to standard chemoimmunotherapy significantly prolongs progression-free survival, a study published in line on June 3 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held June 3-7 in Chicago.

Read the full text

Comments are closed.